氨甲环酸预防慢性硬膜下血肿手术(TORCH):随机安慰剂对照临床试验研究方案
TORCH为随机、安慰剂对照、多中心III期试验,纳入50岁以上、症状轻(GCS≥14、mNIHSS≤4)、中线移位≤10 mm且选择保守治疗的慢性硬膜下血肿患者140例,随机接受氨甲环酸500 mg或安慰剂每日两次共28天,主要结局为12周内是否需手术,结果预计2024年公布。
要点
- 纳入标准:年龄>50岁、GCS≥14、mNIHSS≤4、中线移位≤10 mm且选择保守治疗的cSDH患者。
- 干预:氨甲环酸500 mg或安慰剂每日两次,共28天,随机分组140例。
- 主要结局为12周内是否需手术;次要结局包括血肿体积、神经功能、认知、生活质量等。
核心结论
- 该III期试验旨在评估氨甲环酸预防慢性硬膜下血肿患者手术的疗效,最终结果预计2024年公布。
研究设计与样本
- 随机、安慰剂对照、多中心III期临床试验,计划纳入140例慢性硬膜下血肿患者。
- 纳入标准:年龄>50岁、GCS≥14、mNIHSS≤4、中线移位≤10 mm且选择初始保守治疗。
- 干预:氨甲环酸500 mg或安慰剂每日两次,共28天。
关键数值与推荐
- 主要结局为12周内是否需要手术。
- 次要结局包括12周和6个月时的cSDH体积、mNIHSS、跌倒事件、MOCA、Barthel和Lawton评分、mRS、SF-36和EQ-5D、死亡率及iMCQ和iPCQ。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic subdural haematoma (cSDH) occurs mainly in the elderly. Surgical evacuation is effective, but in these old, often frail, patients with multi-comorbidity, surgery carries significant risks for future cognitive functioning and loss of independency. Therefore, a growing interest is noted for a non-surgical treatment with medication such as tranexamic acid (TXA). In five small retrospective series, this antifibrinolytic drug showed a beneficial effect on the spontaneous resolution of the haematoma, and with that, the necessity for surgery. METHODS: For this randomised, placebo-controlled clinical multicentre trial, all cSDH patients, over 50 years old with mild symptoms (Glasgow Coma Score (GCS) ≥ 14, modified National Institutes of Health Stroke Scale (mNIHSS) ≤ 4), a midline shift of ≤ 10 mm and in whom a primary conservative treatment is chosen, are eligible for study participation. After informed consent, 140 patients will be randomised to receive either TXA 500 mg or placebo two times daily for 28 days. The primary outcome is the necessity for surgery within 12 weeks; secondary outcomes are cSDH volume, neurological impairment (mNIHSS), falling incidents, cognitive functioning (Montreal Cognitive Assessment (MOCA)), performance in activities of daily living (Barthel and Lawton score), functional outcome (modified Rankin Scale (mRS)), quality of life (Short Form Health Survey (SF-36) and EuroQol 5-Dimension Health Survey (EQ-5D)), mortality and the use of care and health-related costs (Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ)) at 12 weeks and 6 months. DISCUSSION: This phase III trial investigating the efficacy of TXA to prevent surgery for cSDH is the first in including patients using anticoagulants and mentally incompetent patients, since these comprise a significant part of the target population. Also, this study is one of the first to prospectively measure functional outcome and quality of life in cSDH patients. Final results of this study are expected in 2024. TRIAL REGISTRATION: Dutch Trial Registry (Nederlands Trial Register) NL6584 . Registered on 11 November 2017 ClinicalTrials.gov NCT03582293 . Registered on 11 July 2018 EU Clinical Trials Register 2017-004311-40 . Registered on 29 March 2018.
引用
- Immenga S, Lodewijkx R, Roos YBWEM, et al. Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial. Trials. 2022. PMID: 35042560. doi:10.1186/s13063-021-05907-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。